
|Videos|March 30, 2016
Dr. Elizabeth Mittendorf on Predictive Biomarkers in Vaccine Treatment for Breast Cancer
Author(s)Elizabeth Mittendorf, MD, PhD
Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses discovering a predictive biomarker response in vaccine therapy for patients with breast cancer.
Advertisement
Elizabeth Mittendorf, MD, PhD, associate professor, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, discusses discovering a predictive biomarker response in vaccine therapy for patients with breast cancer. Mittendorf says this may be because the metastatic environment can be hostile, and moving the therapy to the neoadjvant setting may be the best route for these patients to see results.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5










































